Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT06693102
Starting soon Not applicable

Digital Intervention Targeting Cancer-related Cognitive Impairments

NCT06693102 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2025-01-02
Last updated
2024-11-18

Condition(s) studied

CancerCognitive Impairment

Investigational drug(s) / intervention(s)

Digital intervention targeting cancer-related cognitive impairmentsCrossword and sudoku taks

Digital intervention targeting cancer-related cognitive impairments: The intervention is developed using a person-centered approach and includes key components such as psychoeducation, cognitive training, compensatory strategy training, and cognitive restructuring exercises. Participants receive weekly remote support from a therapist and are encouraged to complete the program within a six-week period.

Crossword and sudoku taks: Participants receive crossword and sudoku tasks. They are encourraged to solve such tasks for a minimum of 15 minutes daily for six weeks.

Study summary

Cognitive deficits are frequently reported following cancer treatment and can significantly impact daily functioning. These cognitive impairments often persist for years after cancer treatment. This study aimed to examine several aspects of a newly developed digital intervention designed to address cognitive impairments. Specifically, it focused on: (1) evaluating the preliminary effects of the intervention, (2) identifying predictors of treatment response, (3) assessing the feasibility of both the intervention and the study design, (4) gathering participant feedback on the intervention, and (5) testing the applicability of the Norwegian version of the Working Memory Questionnaire within this patient group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
The target group consists of individuals who have previously undergone cancer treatment (N=60). Inclusion Criteria: 1. Age between 18 and 65 years, 2. Self-reported cognitive difficulties that are perceived to impact daily functioning (PCI \<44 FACT-Cog), 3. Have received cancer treatment, 4. Completed curative treatment at least six months prior, 5. Proficient in speaking and writing Norwegian, 6. Access to a computer, tablet, or smartphone, and the internet. Exclusion Criteria: 1. Neurological disorders (e.g., ADHD, MS, autism), 2. History of severe head injury, 3. Current moderate or severe depression (PHQ-9 score \>14), 4. Previously diagnosed with serious mental disorders, such as substance abuse, bipolar disorder, or psychotic disorders.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Haukeland University Hospital Bergen Norway

More Haukeland University Hospital trials in Norway

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06693102 on ClinicalTrials.gov ↗ ← All trials in Norway